RADIATION PROTECTION BULLETIN ›› 2019, Vol. 39 ›› Issue (6): 14-18.

Previous Articles     Next Articles

Radiation Protection for Differentiated Thyroid Cancer Patients with 131I Therapy

Gao Hongbo1, Bai Jing1, Li Longmin1, Liu Haichun1, Zhang Xiaoyong1, Shao Yujun1, Pang hua2   

  1. 1. Department of Radionuclide treatment center, Beijing Nuclear Industry Hospital, Beijing, 102413;
    2. Quality control office,Beijing Nuclear Industry Hospital, Beijing, 102413
  • Received:2019-03-21 Published:2019-12-20

Abstract: Patients with differentiated thyroid cancer (DTC) often need 131I treatment after total or subtotal thyroidectomy. When a single dose of 131I exceeds 400 MBq, they need to be hospitalized for isolation. With the continuous increase of DTC patients, 131I treatment is becoming more and more widely used, and the amount of application is getting larger and larger. Associated radiation protection issue has thus attracted widespread attention. Some protective measures and matters, which need to be taken during and after 131I treatment, is presented from the aspects of ward environmental protection, patient self-protection, medical staff protection, and surrounding crowd protection. It’s intended to better protect of patients, medical staff and the public.

Key words: 131I therapy, Radiation protection, Differentiated thyroid cancer(DTC)

CLC Number: 

  • TL75